8:30 AM (PT)
-
This is a three day course requiring attendance on all three days. The Business Development Fundamentals in-person course provides a foundation of the key skills that are required to execute a licensing transaction. With a focus on the biopharma industry, the course is taught by senior executives who have personal experience and expertise in transactional and intellectual property law; business development – both sell and buy sides; finance; alliance management; negotiation, and university technology transfer. Previous attendees include professionals from many international institutions. A sample of companies include: - Alkermes - NIH - American Society of Hematology - Gilead - Amgen - Merck National Taiwan University - Baylor College of Medicine - Novartis - Bluebird Biosciences - Queensland University of Technology - Biogen - Pfizer - Chinese University of Hong Kong - Sanofi - Eli Lilly - Takeda - Evotec - US Army Medical Research - Genentech Course Price: BIO Member: $2,550 Non-Memb ...Course - Additional Fee
8:30 AM (PT)
-
This is a three day course requiring attendance on all three days. The Business Development Fundamentals in-person course provides a foundation of the key skills that are required to execute a licensing transaction. With a focus on the biopharma industry, the course is taught by senior executives who have personal experience and expertise in transactional and intellectual property law; business development – both sell and buy sides; finance; alliance management; negotiation, and university technology transfer. Previous attendees include professionals from many international institutions. A sample of companies include: - Alkermes - NIH - American Society of Hematology - Gilead - Amgen - Merck National Taiwan University - Baylor College of Medicine - Novartis - Bluebird Biosciences - Queensland University of Technology - Biogen - Pfizer - Chinese University of Hong Kong - Sanofi - Eli Lilly - Takeda - Evotec - US Army Medical Research - Genentech Course Price: BIO Member: $2,550 Non-Memb ...Course - Additional Fee
8:30 AM (PT)
-
This is a three day course requiring attendance on all three days. The Business Development Fundamentals in-person course provides a foundation of the key skills that are required to execute a licensing transaction. With a focus on the biopharma industry, the course is taught by senior executives who have personal experience and expertise in transactional and intellectual property law; business development – both sell and buy sides; finance; alliance management; negotiation, and university technology transfer. Previous attendees include professionals from many international institutions. A sample of companies include: - Alkermes - NIH - American Society of Hematology - Gilead - Amgen - Merck National Taiwan University - Baylor College of Medicine - Novartis - Bluebird Biosciences - Queensland University of Technology - Biogen - Pfizer - Chinese University of Hong Kong - Sanofi - Eli Lilly - Takeda - Evotec - US Army Medical Research - Genentech Course Price: BIO Member: $2,550 Non-Memb ...Course - Additional Fee
9:00 AM (PT)
-
This is a one day course requiring attendance for the entire course day. The "Product & Company Valuation" course is designed to teach a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals, or strategic development decisions in the pharma-biotech world. This introductory course is very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors, which shape the risk profile of the company in question. This course optimally balances interactive lectures with practical group work exercises that are designed to help you practice the fundamental valuation tools & techniques taught throughout the day. Valuation is an inherently ...Course - Additional Fee
1:45 PM (PT)
-
Alzheimer’s disease is one of the greatest challenges facing patients, health systems, and society, affecting over 55 million people worldwide. At the intersection of a growing public health crisis, capital pressures, and profound economic burden, the field is at a pivotal inflection point. Addressing it will require diversified investment strategies and cross-sector collaboration that accelerate scientific progress across the full research and development continuum. This panel convenes leaders from biotech, pharma, and philanthropy to examine how innovative science, strategic investment, and collaborative models can unlock the next wave of Alzheimer’s breakthroughs and accelerate progress toward conquering this disease once and for all.Breakout Session 30ABC
3:00 PM (PT)
-
When Emerging Biopharma (EBP) companies consider globalization, what criteria guide their choice of markets to enter? In Japan, the evaluation of innovative new drugs has advanced significantly, creating an environment that is more open and attractive for startups and EBPs than ever before. Support from AMED, PMDA, and other government organizations has expanded, fostering new business opportunities through reforms in pharmaceutical regulations and drug pricing, improvements in clinical trial infrastructure, and increased opportunities for talent exchange and business matching. Japan now stands as a strategic gateway to Asia, especially for US and European startups. This session will share the latest updates and insights from Japan for entrepreneurs exploring opportunities in the Asian region.Breakout Session 29C
-
HBO Max’s “The Last of Us" captivated audiences with its gripping portrayal of a post-apocalyptic world ravaged by a fungal infection. While fictional, the threat posed by fungal pathogens is real. Fungi are adapting to survive in extreme environments and developing resistance to the limited tools available, across human, animal, and environmental health. This panel brings together leaders from biotech, pharma, diagnostics and a venture capital fund to discuss how science, policy, and capital must align to advance antifungal innovation. Panelists will explore lessons learned from developing a novel antifungal class, the role of diagnostics, the value of strategic partnerships, and how One Health aligned strategies and innovative incentive mechanisms could reinvigorate the field.Breakout Session 31C
-
The financing and partnering environment for biotech has shifted significantly in recent years. Investors and partners have increasingly prioritized tangible, de-risked assets that offer compelling therapeutic differentiation and a product roadmap. As a result, the “product-first” model dominates, where clear positioning, validated biology, and a defined regulatory and commercial path are essential to secure financing or partnership interest. Yet companies that can balance a near-term, product-focused strategy with the broader potential of their pipeline are emerging as success stories. Attendees will hear how these companies show that a focused lead asset and a thoughtfully developed pipeline are not mutually exclusive but mutually reinforcing. Their ability to communicate both an immediate value proposition and a credible path to future growth is reshaping how investors assess risk and opportunity in early-stage and emerging biotech ventures.Breakout Session 25ABC
1:45 PM (PT)
-
Precision medicine has transformed oncology, but the next wave is unfolding in new therapeutic areas. The expansion into new areas promises enormous impact, yet the path forward is not straightforward. Outside of oncology, patient populations are more heterogeneous, biomarkers less validated, and regulatory and payor expectations less defined. Unlike oncology, where validated genetic drivers define patient groups, chronic and brain health conditions often lack clear biological anchors. This session will examine the big-picture opportunities and roadblocks for precision medicine’s expansion. Panelists will explore the evolving regulatory framework, payer readiness, and the tools - ranging from digital diagnostics to AI - that could enable precision care at scale. The discussion will draw lessons from oncology’s playbook while highlighting the unique considerations that must be addressed to translate precision into practice across new therapeutic domains.Breakout Session 29C
3:00 PM (PT)
-
AI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this session will highlight practical approaches to monetizing proprietary data and AI platforms, meeting rising standards for data quality, privacy, and model transparency, and accelerating translational and clinical readiness. During this panel, venture investors, experienced operators, and regulatory, licensing and IP experts share a pragmatic playbook for building durable partnerships and navigating commercialization across global life science ecosystems — a conversation that will benefit both investors and AI enabled companies alike. Speakers will emphasize how investors and serial entrepreneurs can position AI driven ventures to stand out through deliberate licensing strategies, defensible data ownership and IP frameworks, and early alignment with global regulatory expectations.Breakout Session 31AB
-
Women’s health is now a dynamic arena for innovation, data science, and strategic capital deployment. This session brings together leading investors to discuss where smart capital is flowing and how science, data, and market infrastructure are driving measurable returns. Speakers will outline how investors identify enduring value, structure partnerships, and capture growth across this rapidly maturing field.Breakout Session 25ABC
11:00 AM (PT)
-
As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detected, stratified, and monitored. Yet these companies often face unique challenges in capital formation. This session brings together investors, entrepreneurs, strategic corporate partners, and non-dilutive funding leaders to examine how financing strategies for diagnostics and precision medicine are evolving in response to these challenges. Panelists will explore how venture, strategic, and public capital assess diagnostic companies across stages, highlighting differences in capital efficiency, timelines, and risk profiles compared to drug development. Attendees will gain practical insights into how diagnostics companies are being financed today, what investors look for at different stages of growth, and how founders can navigate capital formation in a rapidly evolving innovation landscape.Breakout Session 26AB
-
The 36th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotech industry as the operating and regulatory ecosystem is undergoing dramatic changes. There are tectonic shifts in pricing due to Most Favored Nation (MFN) pricing and IRA, FDA policy shifts, NIH funding uncertainties, and supply chain implications due to tariff policies. However, the industry is showing solid innovation, which fuels M&A alliances and venture capital investment. In 2025 the M&A value was $149B up 65% from 2024 and this momentum may carry forward in 2026. This session looks to explore all these topics, and more!Breakout Session 25ABC
1:45 PM (PT)
-
Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, business development activity, and number of drug approvals. Innovation within the oncology pipeline continues to flourish, with novel mechanisms helping counteract the impending loss of exclusivity for several of today’s leading products. But where do industry leaders anticipate future investment to be heading? How are trends in discovery, development, commercialization, and business development impacting how large, mid-size, and small biopharma approach opportunities in oncology? A panel of experts will discuss what the industry can expect in oncology for the remainder of 2026 and beyond.Breakout Session 24BC
3:00 PM (PT)
-
This panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session features four pioneering founders currently building transformative "zero-to-one" companies - those creating entirely new market categories rather than competing in existing spaces. Panelists represent diverse biotech innovations spanning hibernation-based therapeutics, non-invasive vital sign monitoring, epigenetic gene therapies, and gravity-agnostic biotools. This session provides data-driven insights into the funding landscape while delivering actionable strategies for investors, a roadmap from the bench to the boardroom for scientists, understanding emerging technologies that could disrupt traditional approaches for industry veterans, and tactical advice to entrepreneurs from fellow founders building in the hardest environment.Breakout Session 30ABC
-
For decades, autoimmune disease therapy has been defined by one trade-off - suppressing the immune system to relieve symptoms. That paradigm is now breaking. The 2025 Nobel Prize in Physiology of Medicine was awarded for discoveries illuminating how the body maintains immune balance, recognizing decades of research already embedded in novel breakthrough therapeutics in development. From cell therapies inducing drug-free remission in lupus to antigen-specific approaches reprogramming pathogenic memory, the science of immune tolerance - especially through enhancing Tregs - is rapidly shifting from theoretical ambition to a clinical reality. This panel will convene leaders across biotech, pharma, and venture capital to explore how the Immunology & Inflammation field is advancing toward tolerance, how the Nobel-recognized science of immune equilibrium is reshaping R&D strategy, and what investors and partners are watching for as new therapeutic approaches redefine the future of immune medi ...Breakout Session 31C
4:15 PM (PT)
-
Artificial intelligence (AI) has become a widely used label across biotech companies positioning platforms for drug discovery and development. However, what truly defines an AI-marketed platform today goes beyond the presence of advanced algorithms or biological claims. As the industry enters 2026, the central challenge is no longer whether AI can support innovation, but which AI platforms can demonstrate clear return on investment, commercial credibility, and scalability as services for biomedical development that customers are willing to pay for. This session will bring together AI-biotech founders, AI economics experts, and investors to examine what distinguishes successful AI platforms that are marketed and adopted as revenue-generating services rather than as internal programs. Panelists will explore the attributes that enable AI platforms to move from pilot studies to repeat customers, including validation of real-world performance, integration into existing R&D and clinical work ...Breakout Session 31AB
-
Heart disease remains the leading cause of death in the United States, with a person dying every 34 seconds from cardiovascular disease, claiming almost one million American lives every year and accounting for one in every three deaths. For decades, treatment has centered on symptom management and slowing disease progression rather than reversing damage. But the next generation of innovative approaches is challenging the notion that cardiac injury is irreversible, showing that the heart can be repaired, not just supported, by addressing the genetic and molecular drivers of disease itself. This discussion will spotlight the science, novel approaches and new targets driving the next generation of cardiovascular therapies, where the goal is not merely to extend life, but to restore the vitality and resilience of the human heart.Breakout Session 31C
-
Venture capital funding specifically for women’s health biotech and pharmaceuticals has undergone a significant transformation since 2023. While the broader "Women's Health" category is often dominated by "Femtech" (apps, digital platforms, and medical devices), the women’s health biopharma sub-sector is seeing results and advancing assets into the clinic. Join this session to hear about exciting developments in women’s health therapeutics, new partnership models and challenges developers face when researching some of the toughest challenges in women’s health.Breakout Session 26AB
9:00 AM (PT)
-
This session brings together leaders from early-to-late-stage biotech’s and the investment community to explore practical frameworks for transforming early-stage discoveries into development-ready therapeutic assets. Panelists will share concrete examples of early scientific work that has successfully evolved into new biotech companies, illustrating how thoughtful program design, early validation strategies, and milestone-driven execution can bridge the translational gap. The discussion will highlight how effective collaboration models and clear development roadmaps help reduce scientific, operational, and investment risk. Attendees will gain actionable insights into de-risking early-stage science, structuring productive partnerships, and aligning innovation with the expectations of industry and investors to accelerate the path from discovery to real-world therapeutic impact.Breakout Session 29AB
-
In an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and pipeline acceleration. What separates these companies from the rest? What messages, metrics, and milestones resonate most with investors in today’s market? This session brings together biotech CEOs who have each raised $100M+ rounds to share the behind-the-scenes stories of how they did it—what worked, what didn’t, and what they’d do differently next time. From crafting a compelling narrative and building investor confidence to navigating syndicate dynamics and valuation pressure, the discussion will offer actionable insights for founders preparing their next raise.Breakout Session 25ABC
10:15 AM (PT)
-
The path from academic discovery to patient impact has never been more complex. Federal funding shifts, market turbulence, and evolving expectations for commercialization are challenging traditional models of university tech transfer. Yet these pressures are also driving fresh approaches to how institutions partner, de-risk early science, and connect with industry and investors. This session convenes leading translational and academic innovation experts to share how top universities are reimagining models of partnership and entrepreneurship to ensure innovation thrives despite uncertainty. Panelists from MIT, Penn, Yale, and Brown will explore strategies for aligning institutional incentives, strengthening university–industry collaboration, and building regionally connected ecosystems that move discoveries from lab to market faster.Breakout Session 29AB
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}